GenVec's HIV vacc rAD5 enters human trials
US biopharmaceutical firm GenVec says that the first human trial of its adenoviral-vector based HIV vaccine candidate will be conducted at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, in Bathesda, Maryland. The firm explained that the assessment would focus on examining the vaccine's safety when used as a part of a"prime-boost" treatment regimen for HIV-infected individuals.
Originally developed using the firm's proprietary 293-ORF6 cell line, the adenovirus vaccine, referred to as rAD5, is designed to boost the immune response created by the initial use of a DNA priming vaccine. The 15 enrollees will be evaluated in terms of immunogenicity for a 48-week period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze